Novel drugs for treating angina

BMJ (Online)

Volumn 347, Issue 7929, 2013, Pages

  Jones, Daniel A ^a,b   Timmis, Adam ^a,b   Wragg, Andrew ^a,b  

^a Leicester NIHR Biomedical Research Unit in Cardiovascular Disease   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; IVABRADINE; NICORANDIL; NITRATE; PLACEBO; PROPRANOLOL; RANOLAZINE; TRIMETAZIDINE;

ABSCESS; AKINESIA; ANGINA PECTORIS; ANUS FISSURE; APHTHOUS ULCER; ARTICLE; ATRIOVENTRICULAR BLOCK; BLURRED VISION; CARDIOVASCULAR DISEASE; CONSTIPATION; CORONARY ARTERY OBSTRUCTION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FISTULA; FLUSHING; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; MUSCLE HYPERTONIA; NAUSEA; PATIENT MONITORING; PERFORATION; PRIORITY JOURNAL; QT INTERVAL; RECTOVAGINAL FISTULA; RESTLESS LEGS SYNDROME; SIDE EFFECT; STABLE ANGINA PECTORIS; THORAX PAIN; TREMOR; UNSPECIFIED SIDE EFFECT; VASODILATATION; VISION; WEAKNESS;

ACETANILIDES; ANGINA PECTORIS; BENZAZEPINES; ENZYME INHIBITORS; HEART RATE; HUMANS; NICORANDIL; PIPERAZINES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84886936776     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4726     Document Type: Article

References (29)

1. National Institute for Health and Clinical Excellence. Management of stable angina. (Clinical guideline 126.) 2011. http://guidance.nice.org.uk/ CG126.
2. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-164.
3. Procoralan. Summary of product characteristics, EU. Les Laboratories Servier. Last Updated February 2013. www.medicines.org.uk/emc/medicine/17188.
4. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994;8:741-7. (Pubitemid 24376754)
5. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; (19): CD003614.
6. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393-405. (Pubitemid 46425552)
7. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36. (Pubitemid 41677303)
8. Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study. Am J Cardiovasc Drugs 2012;12:179-88.
9. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
10. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):30-4. (Pubitemid 23233988)
11. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(Suppl 3):S74-81.
12. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993;7:119-23. (Pubitemid 23111634)
13. Dargie HJ. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75. (Pubitemid 34310631)
14. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. (Pubitemid 38496341)
15. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316. (Pubitemid 38101603)
16. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75. (Pubitemid 44093970)
17. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36randomized trial. JAMA 2007;297:1775-83. (Pubitemid 46658646)
18. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-8. (Pubitemid 41785931)
19. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2diabetes mellitus and chronic stable angina. Results from the TERISA randomized clinical trial. J Am Coll Cardiol 2013;61:2038-45.
20. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011;120:59-72.
21. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278-86.
22. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74. (Pubitemid 40695027)
23. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31:95-107. (Pubitemid 351175614)
24. Medicines and Healthcare Products Regulatory Agency. Nicorandil 10 mg and 20 mg tablets. 19 Nov. 2011. www.mhra.gov. uk/home/groups/par/documents/ websiteresources/con126150.pdf.
25. ® (ranolazine).2013. A Menarini Pharma UK SRL and www.medicines.org.uk/EMC/ medicine/21402/SPC/Ranexa%20prolongedrelease%20tablets/.
26. European Medicines Agency. European Public Assessment Report (EPAR) Ranexa (ranolazine). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000805/human-med-001009.jsp&murl=menus/medicines/ medicinesjsp& mid=WC0b01ac058001d124.
27. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52. (Pubitemid 47537839)
28. European Medicines Agency. Assessment report for trimetazidine containing medicinal products. 2012. www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/Trimetazidine-31/WC500133925.pdf.
29. Morozova TE, Ivanova EP, Rykova SM. [Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances]. Kardiologiia 2011;51:35-41.